Physician profile
Michael D Stone
NPI 1831177443
$419.13
in general payments reported to CMS, 2019-2025
14 companies · $22.28 in 2025
The $22.28 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $104 · 2021: $38.31 · 2022: $13.84 · 2025: $22.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $62.15 | 2019 | |
| Exelixis INC. | $49.80 | 2019 | |
| Amgen INC. | $48.36 | 2019-2020 | |
| Tris Pharma INC | $44.50 | 2019-2020 | |
| Myovant Sciences INC. | $38.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $29.16 | 2019-2020 | |
| Genzyme Corporation | $28.43 | 2020 | |
| Collegium Pharmaceutical, INC. | $22.28 | 2025 | Jornay Pm |
| Lilly USA, LLC | $21.56 | 2019 | |
| Pfizer INC. | $16.49 | 2019 | |
| Janssen Biotech, INC. | $15.31 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.07 | 2019 | |
| Merck Sharp & Dohme LLC | $13.87 | 2020 | |
| Celgene Corporation | $13.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.